Rapid development through collaborative partnerships
The current status of kinase inhibition provides undeniable evidence of the importance of the “kinase signaling machine” as a viable pharmaceutical target for many disease indications. It also serves as testimony to the incredible resilience of cancer to fight off the intervention.
DNA SEQ’s solutions are focused on learning from cancer patients – and our learning must be fast since cancer is rapidly rejecting our interventions. Our solution is to provide the most comprehensive A/I driven DxRx software platform to “read” the genetic landscape of treated patient responses to kinase targeted drugs, and to translate that to rational methods for an optimal selection from existing drugs, and to build novel three dimensional templates, for mutant defined validated targets, in order to quickly execute modified molecules.
We believe that our patented DxRx platform of A/I technology that utilizes our over 60 million atoms library and the clinical response data of patients is an extremely competitive “tool”. This “tool” has the novel molecular mechanism of kinases signaling with the evolutionary aspect of the kinetics of phosphate kinase signaling embedded within its functionality. Our high diversity, three-dimensional region of the ATP cleft, which was first used to identify “specificity pockets”, appears now to be prime suspect for the drug resistance mechanism selecting different pathway to bypass intervention.
To execute and deliver these predictive products as well as our novel scaffolds for pharmaceutical development, illuminated by the diagnostic insights attained by using our platform, we have selected a model of collaborative engagement with a larger organization with an established infrastructure and marketing ability.
This model will provide the fastest route to our products helping patients fight cancer’s resistance. DNA SEQ’s platform has identified the selected targets. Our platform identifies the genetic landscape of the response of resisting patients and is translated by our DxRx platform in order to provide a specific novel target conformation with novel specificity pockets. A further advantage is provided due to the fact that the “pockets are “screened” by a unique pattern of the ATP cleft residues that are most vulnerable to drug resistance due to the evolution of kinase signaling kinetics.
DNA SEQ is seeking collaborative partnerships to better utilize our patented tools to develop new diagnostic and therapeutic products that can better fight cancer’s resistance. The ALLIANCE consists of a team of extraordinary scientists, each following their own “muse”, in their own organization, but united by the scientific vision of Dr. Sowadski. Our focus has been to create a stable, ethical, and transparent interface where the disciplines and resources could overlap, ideas could be “wrestled with”, and IP could emerge. DNA SEQ’s two patents complete the cycle of discovery to IP.
Just as Dr. Sowadski’s original discovery served as the catalyst for the development of numerous important oncology therapies, we believe that his new discoveries and methodology will serve as the basis for another revolution in cancer diagnostics, treatment, and drug discovery. More specifically, it provides a new understanding of the resistance and a new method to fight it.
TIMELINE OF KEY KINASE INHIBITOR DEVELOPMENT
The X-RAY structure of PKA (“Rosetta Stone”) provided the “structural language” for the catalytic core of entire kinome and provided the first three dimensional model of kinase inhibitor complex.